Targeting GM-CSF in inflammatory and autoimmune disorders.

Semin Immunol

Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria 3050, Australia; Australian Institute for Musculoskeletal Science, St Albans, Victoria 3021, Australia.

Published: April 2021

Granulocyte macrophage-colony stimulating factor (GM-CSF) was originally identified as a growth factor for its ability to promote the proliferation and differentiation in vitro of bone marrow progenitor cells into granulocytes and macrophages. Many preclinical studies, using GM-CSF deletion or depletion approaches, have demonstrated that GM-CSF has a wide range of biological functions, including the mediation of inflammation and pain, indicating that it can be a potential target in many inflammatory and autoimmune conditions. This review provides a brief overview of GM-CSF biology and signaling, and summarizes the findings from preclinical models of a range of inflammatory and autoimmune disorders and the latest clinical trials targeting GM-CSF or its receptor in these disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.smim.2021.101523DOI Listing

Publication Analysis

Top Keywords

inflammatory autoimmune
12
targeting gm-csf
8
autoimmune disorders
8
gm-csf
5
gm-csf inflammatory
4
disorders granulocyte
4
granulocyte macrophage-colony
4
macrophage-colony stimulating
4
stimulating factor
4
factor gm-csf
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!